Ascendis Pharma AS (STU:A710) Cyclically Adjusted PB Ratio: (As of Sep. 07, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:A710 Ascendis Pharma AS STU:A710
46 GF Score
Price €232.00
! 3 Warning Signs
View Full Analysis

What is Ascendis Pharma AS Cyclically Adjusted PB Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PB Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Ascendis Pharma AS  (STU:A710) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Ascendis Pharma AS Cyclically Adjusted PB Ratio Related Terms


Ascendis Pharma AS Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Ascendis Pharma AS's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ascendis Pharma AS Cyclically Adjusted PB Ratio Chart

Ascendis Pharma AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Ascendis Pharma AS Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 29.53

STU:A710 vs JAZZ, BBIO, EXEL: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Ascendis Pharma AS's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ascendis Pharma AS Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ascendis Pharma AS's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Ascendis Pharma AS's Cyclically Adjusted PB Ratio falls into.


STU:A710
46GF Score
Ascendis Pharma AS STU:A710
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ascendis Pharma AS Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Ascendis Pharma AS's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Ascendis Pharma AS's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=21.873/122.9700*122.9700
=21.873

Current CPI (Jun. 2026) = 122.9700.

Ascendis Pharma AS Quarterly Data

Book Value per Share CPI Adj_Book
201609 2.951 100.200 3.622
201612 5.447 100.300 6.678
201703 4.763 101.200 5.788
201706 3.891 101.200 4.728
201709 5.559 101.800 6.715
201712 5.062 101.300 6.145
201803 8.367 101.700 10.117
201806 7.940 102.300 9.544
201809 7.237 102.400 8.691
201812 6.646 102.100 8.004
201903 15.272 102.900 18.251
201906 14.199 102.900 16.968
201909 13.844 102.900 16.544
201912 12.444 102.900 14.871
202003 11.437 103.300 13.615
202006 9.869 103.200 11.760
202009 17.815 103.500 21.166
202012 15.604 103.400 18.557
202103 14.914 104.300 17.584
202106 12.755 105.000 14.938
202109 17.468 105.800 20.303
202112 15.562 106.600 17.952
202203 12.057 109.900 13.491
202206 10.891 113.600 11.789
202209 7.918 116.400 8.365
202212 4.608 115.900 4.889
202303 2.974 117.300 3.118
202306 1.147 116.400 1.212
202309 -1.299 117.400 -1.361
202312 -2.574 116.700 -2.712
202403 -4.169 118.400 -4.330
202406 -5.600 118.500 -5.811
202409 -1.629 118.900 -1.685
202412 -1.766 118.900 -1.826
202503 -3.144 120.200 -3.216
202506 -3.098 120.700 -3.156
202509 -2.849 121.600 -2.881
202512 -2.653 121.200 -2.692
202603 7.899 121.680 7.983
202606 21.873 122.970 21.873

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Ascendis Pharma AS Business Description

Other Exchanges ASND:USAA1SN34:Brazil
Address Tuborg Boulevard 12, Hellerup, DNK, 2900
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.
46GF Score

Get the complete analysis for STU:A710

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€232.00
Price